Telix Pharmaceuticals LimitedASX: TLX

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

· Issued by Telix Pharmaceuticals Limited via PR Newswire

Summary by 6ix AI

Telix Pharmaceuticals has completed enrollment of 105 patients in its pivotal Phase 3 (late-stage) registration study in Japan of TLX591-Px (Illuccix), a kit for preparing the imaging agent 68Ga-PSMA-11, used for prostate cancer imaging in Japanese patients.

Key details

  • The study is prospective, open-label (everyone knows which scan is used) and multicenter. It covers Japanese patients whose prostate cancer has come back on lab tests (biochemically recurrent) after surgical removal of the prostate. The study runs across 11 sites.
  • The main goal is to compare how well 68Ga-PSMA-11 PET/CT (a combined scan) detects cancer that has spread, against conventional imaging including CT and bone scans.
  • Secondary goals include diagnostic performance for local and distant lesions, safety and tolerability, and how imaging findings affect clinical management decisions.
  • Telix is preparing a New Drug Application (a request for approval to market the product) in Japan and intends to use the study's clinical data to support it.
  • Telix has applied to Japan's Pharmaceuticals and Medical Devices Agency (PMDA), the drug regulator, for Conditional Approval. Telix says this would allow a faster review of the New Drug Application while the final study dataset is prepared.

What’s still pending

  • The New Drug Application in Japan is still being prepared and has not been submitted.
  • The Conditional Approval application is under review by the PMDA and has not been granted.

6ix AI wrote this summary from the release below and checked it against the release.

  • Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan.

  • The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan.

MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, "Telix") today announced completion of patient enrollment in the pivotal Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11[1]) for prostate cancer imaging in Japanese patients.

Illuccix Japan[2] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and safety profile of 68Ga-PSMA-11 PET/CT[3] in Japanese patients with biochemically recurrent (BCR) prostate cancer following prior radical prostatectomy. The primary objective of the study is to compare the sensitivity of 68Ga-PSMA-11 PET/CT with conventional imaging modalities, including CT and bone scintigraphy, for the detection of metastatic lesions. Secondary objectives include evaluating diagnostic performance for local and distant lesions, safety and tolerability, and the impact of imaging findings on clinical management decisions.

Telix is preparing an NDA for submission in Japan, with clinical data from the Phase 3 local study intended to support the application. In parallel, Telix's application for Conditional Approval is under review by the Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If granted, Conditional Approval will enable an expedited NDA review process while the final study clinical dataset is prepared.

Completion of enrollment represents a significant milestone for the study and advances Telix's registration strategy for Illuccix® in Japan, one of the world's largest nuclear medicine markets. The study complements Telix's early access and broader prostate cancer portfolio activities in Japan, including named patient use for TLX591-Px[4] and patient enrollment in the Phase 3 ProstACT Global study of TLX591-Tx (lutetium (177Lu) rosopatamab tetraxetan)[5] in advanced prostate cancer.

David N. Cade, MD, Group Chief Medical Officer, Telix, said, "Completion of patient enrollment into this pivotal Phase 3 study was rapid and represents a significant step towards the registration of Illuccix in Japan. We are grateful to the patients, investigators and dedicated study teams across the 11 sites for their commitment to this important study. Together, our goal is to expand access for Japanese men to the benefits of PSMA-PET imaging and thus improve outcomes for men in Japan living with prostate cancer."

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

Later from Telix Pharmaceuticals

All Telix Pharmaceuticals news releases